INVESTORS.

Regulus aims to develop novel oligonucleotide therapeutics that are designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases.

Home Page Ticker

NASDAQRGLS

Latest Quarter.

See all Quarterly Results

Press Releases.

Investor Alerts

November 22, 2023

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

November 09, 2023

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Announced positive topline data from the first cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney...

November 02, 2023

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

More press releases

Events.

6th Annual Evercore ISI HealthCONx Conference

Wednesday, November 29, 2023

10:25am EST

Add to Calendar

Regulus Therapeutics Special Update Call

Wednesday, September 20, 2023

8:30am - 9:30am EDT

H.C. Wainwright 25th Annual Global Investment Conference

Monday, September 11, 2023

11:00am EDT